Drastic changes are brewing at the FDA, as newly appointed Commissioner Dr. Marty Makary indicates a shift toward stricter scientific accountability in vaccine approvals. In a notable departure from ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

The expedited approval of mpox vaccines is critical to addressing this public health emergency. Building on the practice in approving COVID-19 vaccines, this analysis investigates the regulatory ...

With federal public health agencies under the helm of Robert F. Kennedy Jr., a longtime vaccine critic, the usual schedule ...

Novavax ( ($NVAX) ) has risen by 24.00%. Read on to learn why. Novavax has experienced a notable 24.00% increase in its stock price over the past ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of relative weakness. Explore more details here.

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles ...

Novavax’s COVID-19 vaccine is not approved by the FDA yet, but it is available in the U.S. under emergency use authorization, which the FDA issued to the company in July 2022, and allows ...

The FDA authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by next week.